Formulation and Evaluation of Solid Lipid Nanoparticles of BCS Class II Drug

Authors

  • Chitra S Paytode Department of Quality Assurance, Dadasaheb Balpande College of Pharmacy, Besa, Rashtrasant Tukdoji Maharaj University, Nagpur, Maharashtra, India
  • Vinod M. Thakare Department of Quality Assurance, Dadasaheb Balpande College of Pharmacy, Besa, Rashtrasant Tukdoji Maharaj University, Nagpur, Maharashtra, India

DOI:

https://doi.org/10.37591/rrjodfdp.v6i2.503

Abstract

 

In the present study, we explored the potential of antihypertensive drug loaded solid lipid nanoparticles (SLNs), as a new formulation in improving the oral bioavailability of drug, which otherwise reported with poor bioavailability. The problem of poor water-solubility has remained as a significant challenge in pharmaceutical industry. The reduction of drug particle to the nano-level increases the surface area and improves solubility and dissolution of drug and proportionate increase in the bioavailability of poorly water-soluble drugs. Nicardipine is an antihypertensive drug used as model drug to improve its aqueous solubility, dissolution rate and ultimately bioavailability by preparing solid lipid nanoparticles using solvent hot homogenization method. This review aims to provide readers an overview regarding the feasibility and recent applications of SLNs as an increasing solubility of poorly water-soluble antihypertensive drugs.


Keywords: BCS Class II drug, nanoparticles, Nicardipine, coemulsifier, sacroplasmic reticulum

Cite this Article

Chitra S. Paytode, Vinod M. Thakare. Formulation and Evaluation of Solid Lipid Nanoparticles of BCS Class II Drug. Research & Reviews: A Journal of Drug Formulation, Development and Production. 2019; 6(2): 32–54p.


Downloads

Published

2019-09-11

Issue

Vol. 6 No. 2 (2019)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.